Proffered Paper session – Breast cancer, early stage

Channel 5 Friday, 17 September, 08:30—09:50119O Event-free survival (EFS), overall survival (OS), and safety of adding veliparib (V) plus carboplatin (Cb) or carboplatin alone to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) after ≥4 years of follow-up: BrighTNess, a randomized phase III trial
Presentation LBA11: Individual patient data Meta-Analysis of 5 Non-Inferiority RCTs of Reduced Duration single agent adjuvant Trastuzumab in the treatment of HER2 positive Early Breast Cancer


Presidential symposium 1
Channel 1 Saturday, 18 September, 10:05—11:35
Trastuzumab Deruxtecan (T-DXd) vs Trastuzumab Emtansine (T-DM1) in Patients (Pts) With HER2+ Metastatic Breast Cancer (mBC): Results of the Randomized Phase 3 DESTINY-Breast03 Study

MINI ORAL SESSION : Breast cancer, metastatic
Channel 1 Saturday, 18 September, 12:30—13:20

Presentation 229MO : Overall Survival (OS) of palbociclib (P) plus endocrine therapy (ET) versus capecitabine (CAP) in hormone-receptor+/HER2- metastatic breast cancer (MBC) that progressed on aromatase inhibitors (AIs). Final results of the PEARL study.
Presentation 228MO : PALOMA-4: Primary results from a phase 3 trial of palbociclib (PAL) + letrozole (LET) vs placebo (PBO) + LET in Asian postmenopausal women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative (ER+/HER2–) advanced breast cancer (ABC)
Presentation LBA19 : A multicenter, randomized, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (mBC) (DESIREE)



PROFFERED PAPER SESSION: Breast cancer, metastatic
Channel 1 Sunday, 19 September, 08:30—09:52

Presentation LBA15 : Primary outcome of the phase III SYD985.002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician’s choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer
Presentation LBA16 : KEYNOTE-355: Final results from a randomized, double-blind phase 3 study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC

Presentation LBA17_PR : Overall survival (OS) results from the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2_) advanced breast cancer (ABC) treated with endocrine therapy (ET) _ ribociclib (RIB)



MINI ORAL SESSION Breast cancer, early stage
Channel 1 Monday, 20 September, 12:30—13:30

Presentation LBA12 : Predictive value of gene-expression profiles (GEPs) and their dynamics during therapy in the NeoTRIPaPDL1 trial
Presentation 121MO : Acute toxicity associated with a 3-week versus a standard 5-week regimen for locoregional breast radiotherapy delivered in the Unicancer HypoG-01 phase III Trial